Bio-Techne Q3 FY2024: Revenue $303.4M (+2% organic); GAAP EPS $0.31 vs $0.43; declares $0.08 dividend

BIO-TECHNE Corp

2024-Q3 EPS reported $0.79 revenue$852,961,000

Q3 revenue $303.4M (organic +2%, reported +3%); GAAP EPS $0.31 vs $0.43; adjusted EPS $0.48 vs $0.53.
Diagnostics & Genomics segment organic growth 10% (reported 16%); record GMP reagent sales in cell/gene therapy.
Cash from operations $223.5M, up 31% YoY.
Quarterly dividend of $0.08 per share, payable May 24, 2024; record date May 13, 2024.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

BIO-TECHNE Corp reported the third quarter ending March 31, 2024 results: revenue $303.4 million, EPS $0.31.

Period: the third quarter ending March 31, 2024
Revenue: $303.4 million
EPS: $0.31
Result: reported results

Exact text from the filing

reported its financial results for the third quarter ending March 31, 2024. Third Quarter FY2024 Highlights ● Third quarter organic revenue increased by 2% (3% reported) to $303.4 million. ● GAAP earnings per share (EPS) was $0.31 versus $0.43 one year ago. Delivered adjusted EPS of $0.48 compared to $0.53 one year ago. ● Strong commercial execution in

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-TECHNE Corp filing history →

Source: SEC EDGAR

accession 0001558370-24-006319

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.